Burkholderia cepacia FAQs
The Burkholderia cepacia complex (B. cepacia) consists of several species of bacteria that are found in the natural environment. Some of these species threaten the health of people with cystic fibrosis (CF). There are about 17 different B. cepacia complex species. The ones most often found in people with CF are:
B. gladioli, although not a member of B. cepacia complex, is another Burkholderia species that can be found in the lungs of people with CF.
Burkholderia bacteria are often resistant to many antibiotics, which makes them difficult to treat once they infect the lungs. However, some species may be successfully treated with combinations of antibiotics.
Basic infection prevention and control practices reduce the risk of getting or spreading an infection. These bacteria pose very little medical risks to healthy people. However, some people who have a serious illness (e.g., cancer, AIDS) may be at risk of an infection from these bacteria.
How B. cepacia complex species affect people with CF varies. Researchers do not yet know why some people with CF are more likely to get B. cepacia complex than other people are.
In many people, infection with B. cepacia complex may not worsen lung disease. In up to one-third of people infected with B. cepacia complex, the rate of lung function decline appears to be slightly faster. However, for a smaller number of people, B. cepacia complex can cause a rapid decline in lung function and health. This leads to more severe lung disease and maybe death.
Among the different species of B. cepacia complex, some may be more harmful than others, e.g., B. cenocepacia and B. dolosa. The CF Foundation is working with researchers to learn more about the B. cepacia complex and to identify new treatments.
It is not always known how people with CF become infected with B. cepacia complex. Research has shown that people with CF can get B. cepacia complex from others who are infected with these bacteria. The germs spread either by direct contact, such as kissing, or indirectly from touching objects with the germs, such as doorknobs. This can happen in social settings, such as events or meetings.
In some cases, shared B. cepacia infection was not found in the lungs of a person with CF until two years after being exposed to someone else who was infected with this germ.
For many people with CF, infection with B. cepacia complex cannot be traced back to exposure to another infected person. In these cases, infection is believed to have occurred by exposure to Burkholderia in the natural environment.
At a CF care center, the staff works to prevent the spread of B. cepacia complex between people with CF by doing infection prevention and control measures. These include frequent cleaning of hands, wearing gowns and gloves, separating people with B. cepacia complex when admitted to the hospital and seeing them in the clinic in different locations or on different days.
CF Foundation-accredited care centers also follow strict procedures when cleaning clinic rooms, pulmonary function labs and respiratory therapy equipment to reduce the risk of spreading germs.
Please ask the CF care center staff about their efforts to minimize risks of getting or spreading germs between people with CF.
When a doctor or nurse gets a throat or sputum culture from a person with CF, it is handled differently in the laboratory to help find any B. cepacia complex species. Ask your CF care center about the results of your last throat or sputum culture.
However, medical evidence shows that all people with CF could have germs that might spread to others with CF. Plus, sputum cultures may not find all germs that could spread among those with the disease.
The CF Foundation supports the Burkholderia cepacia Research Laboratory and Repository at the University of Michigan, Ann Arbor. Care centers can send sputum cultures there to confirm and identify the specific species of B. cepacia complex.
The CF Foundation is supporting research on B. cepacia complex to find new ways to prevent or get rid of lung infections caused by these bacteria in people with CF. Some researchers are studying whole new classes of antibiotics to fight B. cepacia complex bacteria.
In addition, basic research is underway to describe the differences between the B. cepacia complex species. The CF Foundation supports the B. cepacia Research Laboratory and Repository at the University of Michigan, Ann Arbor. This lab is doing basic research on these bacteria.
The laboratory is a resource to the CF medical community to identify B. cepacia complex species, investigate their spread and store samples for future research studies. Also, This laboratory enables scientists to learn more about how B. cepacia causes infection and to help find new treatments for people with CF.
According to the CF Foundation’s 2012 National Patient Registry, 2.6 percent of all people with CF receiving care at CF Foundation-accredited care centers have B. cepacia complex. This percentage varies between care centers.